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The antioxidant response element (ARE) and its transcription factor, nuclear factor-erythroid 2 p45-related factor 2 (Nrf2), are
potential targets for cancer chemoprevention. We sought to screen small molecules synthesized with combinatorial chemistry for
activation of ARE. By high-throughput screening of 9400 small molecules from 10 combinatorial chemical libraries using HepG2
cells with an ARE-driven reporter, we have identiﬁed a novel small molecule, 1,2-dimethoxy-4,5-dinitrobenzene (LAS0811), as
an activator of the ARE. LAS0811 upregulated the activity of NAD(P)H:quinone oxidoreductase 1 (NQO1), a representative
antioxidativeenzymeregulatedbyARE.Itenhancedproductionofanendogenousreducingagent,glutathione(GSH).Inaddition,
LAS0811 induced expression of heme oxygenase 1 (HO1), which is an ARE-regulated enzyme with anti-inﬂammatory activity.
Furthermore, LAS0811 reduced cell death due to the cytotoxic stress of a strong oxidant, t-butyl hydroperoxide (t-BOOH).
Mechanistically, LAS0811 upregulated the expression of Nrf2 and promoted its translocation into the nuclei leading to subsequent
ARE activation. Taken together, LAS0811 is a novel activator of the ARE and its associated detoxifying genes and, thus, a potential
agent for cancer chemoprevention.
Copyright © 2009 Ming Zhu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Chemoprevention is a promising strategy to prevent cancer
by employing small molecules to enhance production of
phase II detoxifying enzymes which are capable of scav-
enging carcinogens [1]. A number of structurally unre-
lated molecules, such as anethole dithiolethiones, curcumin,
isothiocyanates, caﬀeic acid, phenethyl esters, ﬂavonoids,
and triterpenoids, have been shown to activate ARE and
subsequent induction of the phase II detoxifying enzymes
[2, 3]. The ARE was ﬁrst discovered and named by Pickett
and his colleagues [4]. A fuller characterization of the DNA
consensus sequence required for ARE activity, including
the requirement of 5 -ﬂanking sequences, was subsequently
reported by Wasserman and Fahl [5]a n db yN i o ie ta l .[ 6].
The ARE is a cis-acting element located in the promoter
region of a number of genes encoding phase II detoxifying
enzymes and antioxidative proteins [7, 8]. These enzymes
and proteins include NAD(P)H:quinone oxidoreductase
1 (NQO1), glutathione S-transferase (GST), γ-glutamate-
cysteine ligase (GCL), heme oxygenase 1 (HO1), thioredoxin
reductase-1, and thioredoxin.
Activation of ARE is regulated by a transcription
factor, Nrf2, a member of the Cap‘n’Collar family of
transcription factors that share a highly conserved basic
leucine-zipper region [9]. It has been shown that Nrf2
is normally sequestered in the cytoplasm as an inactive
complex with Kelch-like ECH-associated protein 1 (Keap1).
In response to certain extracellular stimuli, Nrf2 dissociates
from Keap1 and translocates into the nucleus, where Nrf2
heterodimerizes with a small Maf protein binds to the ARE
and, subsequently, activates transcription of ARE-dependent
genes [10]. However, other mechanisms of regulation of
Nrf2, including stabilization of the Nrf2 protein by its
inducers, have also been proposed and recently reviewed by
Hayes and McMahon [11]. The Nrf2/ARE signaling pathway2 Journal of Biomedicine and Biotechnology
apparently plays an important role in cellular protection
in response to oxidative stresses [12]. For example, Nrf2-
deﬁcient mice are more susceptible than wild-type mice
to oxidative injury and chemical-induced carcinogenesis
[13]. Therefore, the Nrf2/ARE signaling pathway is a logical
target for identifying novel chemopreventive agents [14,
15].
In the current study, we report the identiﬁcation of
a novel ARE activator, 1,2-dimethoxy-4,5-dinitrobenzene
(LAS0811), by screening 10 combinatorial libraries of small
molecules using an ARE-driven reporter assay.
2.MaterialandMethods
2.1. Chemicals and Reagents. t-Butylhydroquinone (tBHQ),
reduced glutathione (GSH), dicumarol, ﬂavin adenine dinu-
cleotide (FAD), β-nicotinamide adenine dinucleotide phos-
phaste (NADP), glucose-6-phosphate, glucose-6-phosphate
dehydrogenase, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), menadione, metaphosphoric
acid, and t-butyl hydroperoxide (t-BOOH) were purchased
from Sigma Chemical Co. (St. Louis, MO); Dc Protein Assay
kit from Bio-Rad Labs (Hercules, CA); and GSH-400 assay
from Oxis International Inc. (Foster City, CA).
2.2. Combinatorial Libraries. Ten combinatorial chemical
libraries, consisting of 9400 small molecules, were synthe-
sized as a part of a combinatorial chemistry program in our
institution. As shown in Figure 1,e a c hl i b r a r yw a sg e n e r a t e d
from reactions of a basic chemical scaﬀold with diﬀerent
building blocks using methods as previously reported by
us [16–22] .T h ep u r i t yo fe a c hc o m p o u n dw a sc o n ﬁ r m e d
to be at least 98% as analyzed by high-pressure liquid
chromatography. They were kept in dimethyl sulfoxide
(DMSO) in 96-well plates.
2.3. Cell Cultures. A human hepatocellular carcinoma cell
line, HepG2, was obtained from American Type Culture
Collection (Rockville, MD). This cell line was maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum,
100U/mL of penicillin, and 100U/mL of streptomycin
(GibcoBRL, Grand Island, NY) in a humidiﬁed atmosphere
of 5% CO2 and 95% air at 37◦C.
2.4. In Vitro Model of ARE Activation. An in vitro model for
regulation of ARE has been developed by stable transfection
into the HepG2 cells, a reporter gene of green ﬂuorescent
protein (GFP) driven by four copies of ARE and a thymidine
kinase (TK) promoter as previously described by us [23].
The expression of GFP was inducible in the HapG2 cells
transfected only with the ARE/TK-GFP construct but not
with the TK-GFP construct. Level of ﬂuorescence emitted by
GFP reﬂected degree of ARE activation. This assay has been
validated by applying various well-known activators of ARE
including tBHQ [24].
2.5. Screening of Chemical Libraries for ARE Activation. Each
small molecule was diluted with DMEM, and the maximal
concentration of DMSO in each assay was not to exceed
0.25%. The HepG2 cells harboring the ARE/TK-GFP were
seeded into wells (4 × 104 cells per well) of a 96-well plate
and allowed to attach overnight. The cells were exposed to
each test compound, at a concentration of 10μM, for 24
hours, with tBHQ serving as a positive control. The medium
was removed and 100μL of phosphate-buﬀered saline (PBS)
was added to each well. Fluorescent intensity, which was
an indicator of the level of GFP expression, was measured
at the excitation/emission wavelengths of 485/530nm using
a ﬂuorescent microplate reader. The relative density of
live cells was determined using the MTT assay [25]. The
ﬂuorescent intensity of GFP was normalized to density of
live cells in each well by dividing the ﬂuorescent intensity
to the absorbance, at 570nm, of the formazan dye formed
from MTT by the live cells. Compounds, which showed
enhancement of relative ﬂuorescent intensity equal to or
higher than tBHQ, were selected for secondary screening at
concentrations ranging from 0.1μMt o3 0μM in triplicates.
Cytotoxicity of the lead compounds was also determined
over a dose range of 0 to 100μM using the MTT assay.
2.6.MeasurementofDown-StreamMarkersofAREActivation.
To further conﬁrm the activation of ARE by LAS0811, the
following down-stream markers of ARE in the HepG2 cells
were measured.
2.6.1. NQO1 Activity. HepG2 cells were exposed to 0 to
30μM of LAS0811 for 24 hours. Cellular NQO1 activity
was quantiﬁed using a microtiter-plate-based spectroscopic
assay [26]. Cell pellets were sonicated in 150μL of PBS and
c e n tri f u g e da t1 20 0 0ga t4 ◦C for 5 minutes. The supernatant
fraction was diluted with 10mM Tris-HCl buﬀer, pH 7.4. To
exclude nonspeciﬁc enzymatic activity, 50μL of the buﬀer
containing 0.3mM of dicumarol was added to parallel wells
in place of the regular buﬀer. Next, 200μL of an assay solu-
tion, containing Tris-HCl (25mM, pH 7.4), bovine serum
albumin (BSA) (0.5%), Tween 20 (0.025%), FAD (5μM),
NADP (30μM), glucose-6-phosphate (1μM), glucose-6-
phosphate dehydrogenase (2U/mL), MTT (0.3mg/mL), and
menadione (25μM), was added to each well. The reaction
rate was immediately measured at 610nm for 5 minutes
using a microtiter plate reader.
2.6.2. GSH Level. HepG2 cells were exposed to 0 to 30μMo f
LAS0811 for 24 hours. Cellular GSH level was determined
using a GSH-400 assay kit (Oxis International, Inc, Foster
City, CA). Each cell pellet was resuspended and sonicated
in 4 volumes of ice-cold 5% metaphosphoric acid. The
lysates were centrifuged at 10000g at 4◦Cf o r5m i n u t e s .
Each supernatant fraction (∼30μL) was mixed with 90μL
of reaction buﬀer and 5μL of chromogenic reagent followed
by 5μL of 30% NaOH. After incubation for 10 minutes, the
absorbance at 400nm was measured with a microtiter plate
reader. A calibration curve of GSH was constructed using
commercially available GSH.Journal of Biomedicine and Biotechnology 3
H
N
O
O
O
O O
O
O
O
O
Library L-6
Library L-10
Library L-7 Library L-8
N
N
N
HN
N
NH2
NHAr
R1
R1 R2
R2
R1HN
R2HN
R2
O
O
S
O
O
N
O
O O
O
S
O
X
X = O, NH
O
O
O O O O
O
Library L-4 Library L-3 Library L-2 Library L-1
Library L-5
Library L-9
N
N N
N N
N
N
N
HN
NH2
NH2
NH2
NH2 NH2
NH2
NH
NO2
R1 R1 R1
R1
R1
R1
R1
R2 R2
R2
R2
R2
R2
R3
O2N
O2N
O2N
H2N
Figure 1: General chemical structures of 10 combinatorial libraries of small molecules, which were screened with the HepG2/ARE-GFP
cells. R1,R 2, and R3 are alkyl or aryl groups. LAS0811 was identiﬁed from library L-9.
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Figure 2: Chemical structures of LAS0811 and tBHQ.
2.6.3. HO1 Expression. HepG2 cells were exposed to
LAS0811 at 0 to 50μM for 24 hours. Whole-cell lysates were
prepared by suspending cell pellets in Cellytic M lysis reagent
(Sigma, St. Louis, MO). After centrifugation at 10,000g,
supernatants were collected and protein concentrations were
determined using the Dc Protein Assay kit (Bio-Rad). Equal
amounts of lysate protein were analyzed on a 10% SDS-
polyacrylamine gel and transferred onto a nitrocellulose
membrane. The membrane was probed with a rabbit anti-
human HO1 primary antibody (Santa Cruz Biotechnology
Inc,SantaCruz,CA)followedbyagoat-antirabbitsecondary
antibody conjugated with horseradish peroxidase. Detec-
tion was accomplished with the ECL reagents (Amersham
Pharmacia Biotech, Piscataway, NJ). The relative level of
expression of HO1 was determined by dividing the density
of each band of HO1 to that of β-actin as detected by a
densitometer.
2.7. Protection against t-BOOH-Induced Cytotoxicity. t-
Butyl hydroperoxide (t-BOOH) is a strong oxidant and
highly cytotoxic. The antioxidative eﬀect of LAS0811 was
demonstrated by its potency of protecting HepG2 cells
from the t-BOOH-induced cytotoxicity. HepG2 cells were
plated in a 96-well plate (4 × 104 cells per well). After
incubating overnight, cells were pretreated with LAS0811 at
concentrations of 0 to 100μM for 24 hours. The culture
medium was replaced with fresh medium containing 1mM
of t-BOOH and the cells were incubated for an additional
10 hours. Cell cytotoxicity was measured with the MTT
assay.
2.8. Upregulation and Translocation of Nrf2. To investigate
if the activation of the ARE-dependent genes by LAS0811
was associated with a concomitant upregulation and nuclear
translocation of Nrf2, we examined the appearance of the
Nrf2 protein in cytoplasm and nuclei in the HepG2 cells
followingexposuretoLAS0811.TheHepG2cellsweregrown
on glass cover slides overnight, and exposed to LAS0811
at concentrations of 0 to 30μM for 3 and 18 hours. The
cells were probed with a rabbit antihuman Nrf2 antibody
(Santa Cruz Biotechnology, Inc. Santa Cruz) followed by
a secondary swine antirabbit IgG conjugated with FITC.
The nuclei were counter-stained with 4 ,6-diamidino-2-
phenylindole (DAPI). The glass slides were examined under
a deconvolution ﬂuorescent microscope.4 Journal of Biomedicine and Biotechnology
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Figure 3: (a) Fluorescent images of the HepG2/ARE-GFP cells with no treatment or treatment with DMSO (0.5%), LAS0811 (30μM,
24 hours), or tBHQ (30μM, 24 hours). Magniﬁcation ×100. (b) Dose-dependent upregulation of expression of the ﬂuorescent GFP after
exposure of the HepG2/ARE-GFP cells to LAS0811 or tBHQ for 24 hours. Mean ± SD, n = 3.
2.9. Statistical Analysis. Each assay was performed at least
3 times. Results were expressed, where appropriate, as
mean ± standard deviation (SD). Student’s t-test was used
to determine statistically signiﬁcant diﬀerence (P<. 05)
between treatment groups.
3. Results
3.1. Screening of Combinatorial Libraries for ARE Activation.
Upon screening 10 combinatorial chemical libraries consist-
ing of 9400 small molecules (Figure 1), we have identiﬁed,
from library L9, one novel compound, 1,2-dimethoxy-4,5-
dinitrobenzene (LAS0811), which consistently induced ARE
activation higher than the prototype activator of ARE,
tBHQ. Many analogs of each library weakly activated ARE
(i.e., the enhancement of ﬂuorescence was less than 50%
of that induced by tBHQ). There was no known ARE-
activator within each library. The structures of LAS0811
and tBHQ are shown in Figure 2. LAS0811 and tBHQ
were not autoﬂuorescent. The HepG2 cells harboring the
ARE/TK-GFP expressed a low basal level of ﬂuorescence.
Upon exposure of the cells to tBHQ or LAS0811 over
24 hours, the GFP expression was enhanced as shown in
Figure 3(a).TheinductionofGFPexpressionbyeithertBHQ
or LAS0811 was dose-dependent as shown in Figure 3(b).
LAS0811 induced GFP expression signiﬁcantly higher than
tBHQ over the concentration range of 1 to 30μM. LAS0811
induced GFP expression by 130% and 225% over the
baseline at 5μMa n d3 0μM, respectively. The level of GFP
expression induced by LAS0811 was signiﬁcantly higher
than that induced by tBHQ (P<. 05). Of note, the
LAS0811 was not cytotoxic to the HepG2 cells over the
concentration range of 0 to 50μM as determined by the
MTT assay. At 100μM, the viability of HepG2 cells was
90%.
3.2. Induction of NQO1 Activity, GSH and HO1 Expressions.
After exposure of the HepG2 cells to LAS0811 for 24
hours, the NQO1 activity was increased in a dose-dependent
manner as shown in Figure 4(a). The NQO1 activity was
increased signiﬁcantly by 20%, 52%, and 100% with 5, 10,
and30μMofLAS0811,respectively.Similarly,theGSHlevels
were signiﬁcantly increased by 25%, 54%, and 143% with
5, 10, and 30μM of LAS0811, respectively, as shown in
Figure 4(b). LAS0811, at concentrations of 10 and 50μM,
signiﬁcantly upregulated the expression of the HO1 protein
by 2- and 4-fold, respectively, of the HepG2 cells as shown in
Figure 5.
3.3. Protection of t-BOOH-Induced Cytotoxicity. Pretreat-
ment with LAS0811 signiﬁcantly protected HepG2 cells
againstt-BOOH-inducedoxidativecytotoxicity.Ataconcen-
tration of 1mM, t-BOOH reduced viability of the HepG2
cells to 16% of the control. Preexposure of the cells to
LAS0811 for 24 hours signiﬁcantly increased cell viability to
50% at 5μM and 72% at 30μM as shown in Figure 6.
3.4. Upregulation and Translocation of Nrf2. The time
course of appearance of Nrf2, as detected with ﬂuorescent
microscopy, in the cytoplasm and nuclei of the HepG2 cells
in response to LAS0811 exposure is shown in Figure 7.
Enhancement of Nrf2 expression was detected in the cyto-
plasm 3 hours after exposure to 30μM of LAS0811. By
18 hours, the Nrf2 protein was noticeably located in the
nuclei as well as in the cytoplasm. These results indicated
that LAS0811 upregulated the expression of Nrf2 in the
cytoplasm and promoted its subsequent translocation from
the cytoplasm into the nuclei.Journal of Biomedicine and Biotechnology 5
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Figure 4: Dose-dependent increase of (a) NQO1 activity; (b) GSH
level,afterexposureoftheHepG2cellstoLAS0811at1to30μMf o r
24 hours. Mean ± SD, n = 3.
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Figure 5: Eﬀect of LAS0811 on HO1 expression in HepG2 cells:
Dose-dependent response to LAS0811 at 0, 10, and 50μMf o r2 4
hours.
4. Discussion
Induction of the Nrf2/ARE-regulated proteins, which detox-
ify potential carcinogens and oxidants, represents a promis-
ing strategy for cancer prevention. In this regard, many
potential chemopreventive agents with a variety of chemical
structures have been identiﬁed [2, 3]. However, clinical
application of these agents has been hampered by their
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Figure 6: Dose-dependent enhancement of cell viability by
LAS0811 of the HepG2 cells exposed to a cytotoxic oxidant, t-
BOOH. HepG2 cells were pretreated with LAS0811 at 0 to 30μM
for24hoursfollowedbyexposureto1mMoft-BOOHfor10hours.
Mean ± SD, n = 3.
toxicity or ineﬀectiveness in human subjects [27]. Therefore,
the eﬀort for searching of safe and eﬀective chemopreventive
agents continues.
Combinatorial chemistry is a powerful technology in
simultaneously generating thousands of unique chemical
entities [28]. We have generated 10 combinatorial chemical
libraries of 9400 unique small molecules. Together with a
high-throughput cell-based ARE functional assay, we have
screenedtheselibrariesandidentiﬁedanovelsmallmolecule,
LAS0811, which activates the Nrf2/ARE signaling pathway.
LAS0811, at 30μM, enhanced expression of the GFP protein
by more than 200% with the cell-based model of GFP, yet the
induction of expression or activity of GSH, HO1, and NQO1
varied from 100% to 200%. The degree of upregulation
of the diﬀerent down-stream proteins was not identical
as their regulatory mechanisms along the Nrf2/ARE axis
may vary. We do not know if the metabolites of LAS0811
are biologically active as LAS0811 may be subjected to O-
demethylation. Nevertheless, we have demonstrated that
LAS0811 itself is an activator of ARE in all the in vitro assays
conducted to date.
Firstly, LAS0811 protects cells from cytotoxicity of a
strong oxidant, t-BOOH. We speculate that this protective
eﬀectisattributed,atleastinpart,toenhancementofexpres-
sion and activity of the Nrf2/ARE-regulated cytoprotective
genes as recently reported by Higgins et al. for sulforaphane
[29]. Pretreatment of Nrf2+/+ mouse embryonic ﬁbroblasts
(MEFs) for 24 hours with an inducing dose of sulforaphane
conferred 1.6-fold resistance against t-BOOH. In contrast,
Nrf2−/− MEFs were 3-times more sensitive to t-BOOH
than Nrf2+/+ MEFs and could not be protected against
the peroxide by pretreatment with sulforaphane. In the
current study, we have shown that LAS0811 enhanced the
activity of NQO1 and increased the level of GSH. NQO1
plays an important role in protecting cells against ROS and
maintaininggenomicstability[30].Thisenzymemetabolizes
highly toxic and reactive quinone species, maintains redox
homeostasis,andstabilizesthehalf-lifeofatumorsuppressor6 Journal of Biomedicine and Biotechnology
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Figure 7: Fluorescent microscopy of Nrf2 expression in the cytoplasm and nuclei of HepG2 cells treated with 30μM of LAS0811 for 0, 3,
and 18 hours. DAPI was used to identify the nuclei. Magniﬁcation ×200.
protein, p53 [31]. On the other hand, GSH is the most
abundant reducing thiol in mammalian cells. It plays an
importantroleindetoxifyingROSandservesasacofactorfor
several peroxidases [32]. Intracellularly, GSH is synthesized
consecutively by GCL and glutathione synthase. The rate-
limitingGCLisregulatedviatheAREsignalingpathway[33].
Secondly, LAS0811 upregulates the expression of the
enzyme, HO1, which possesses antioxidative, antiinﬂamma-
tory and antiapoptotic activity [34, 35]. It is the rate-limiting
enzyme in the conversion of heme into biliverdin, carbon
mono xideandfreeiron.Thefreehememoietyisapotentially
toxic pro-oxidant. Biliverdin is very rapidly converted to
bilirubin by the enzyme biliverdin reductase. Bilirubin is
an antioxidant capable of scavenging peroxy radicals and
inhibiting lipid peroxidation [36]. Carbon monoxide is
also believed to play a role as a signaling molecule in
the antiinﬂammatory and antiapoptotic pathways [37]. The
expression of the HO1 gene is regulated mainly through the
Nrf2/ARE pathway as it contains multiple copies of ARE
sequences in its promoter [38]. It has also been shown
that the expression of HO1 can be induced through other
signalingpathways,suchasMAPKsandPI3K-dependentAkt
[39, 40]. Whether these signaling pathways are involved in
the LAS08111-mediated induction of HO1 remains to be
delineated.
Lastly, LAS0811 enhances expression of Nrf2 in the
cytoplasm and promotes its translocation into the nuclei.
In concurrence with other investigators concerning the
role of Nrf2, LAS0811 enhances expression of Nrf2 in the
cytoplasm followed by its subsequent translocation into
the nuclei in the HepG2 cells. In addition to the HepG2
cells, we have also observed similar phenomenon in an
immortalized human bronchioepithelial cell line, HBE, and
an immortalized mouse hippocampal cell line, HT22 (data
not shown). We propose two possible mechanisms involved
in the upregulation of Nrf2. First, the LAS0811 may act
directly on ARE and induce Nrf2 expression based on the
observationthatexpressionofNrf2itselfisregulatedviaARE
[41]. Second, LAS0811 may interrupt the binding of Nrf2
with Keap1 which binds and keeps Nrf1 in the cytoplasm.
Dissociation of Nrf2 from Keap1 results in the availability of
free Nrf2 and its subsequent translocation into the nuclei.
In summary, we have identiﬁed a novel small molecule,
LAS0811, which activates the ARE/Nrf2 pathway. LAS0811
is being investigated as a chemopreventive agent in animal
models.
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ARE: Antioxidant response element
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GCL: γ-glutamate-cysteine ligase
HO1: Heme oxygenase-1
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NQO1: NAD(P)H:quinone oxidoreductase 1
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